AAP
FATE icon

Ardsley Advisory Partners’s Fate Therapeutics FATE Stock Holding History

Ardsley Advisory Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,500
Closed -$257K – 159
2020
Q2 		$257K Buy
+7,500
New +$224K 0.05% 112

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ardsley Advisory Partners's FATE Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of Fate Therapeutics (FATE) in Q3 2020, closing a stake of 7,500 shares — an estimated $257K sold.

Ardsley Advisory Partners first reported a position in FATE in Q2 2020 and held it in 1 quarter. The position peaked at $257K in Q2 2020. 211 funds tracked by Wall St. Rank hold FATE as of Q3 2020.

  • Ardsley Advisory Partners reported no remaining Fate Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 7,500 Fate Therapeutics shares in Q3 2020, an estimated $257K.
  • Ardsley Advisory Partners first reported a position in Fate Therapeutics in Q2 2020 and held it in 1 quarter.
  • Ardsley Advisory Partners's Fate Therapeutics position peaked at $257K in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.